-
公开(公告)号：US20120219615A1
公开(公告)日：2012-08-30
申请号：US13252147
申请日：2011-10-03
申请人： Robert Hershberg , George Coukos , Gregory Dietsch , Andrea Facciabene , Kristi Manjarrez , Tressa D. Randall
发明人： Robert Hershberg , George Coukos , Gregory Dietsch , Andrea Facciabene , Kristi Manjarrez , Tressa D. Randall
IPC分类号： A61K31/55 , A61K31/7068 , A61K31/664 , A61N5/00 , A61K9/127 , A61K39/395 , A61K38/22 , A61K38/19 , A61K31/704 , A61P35/00
CPC分类号： A61K31/55 , A61K9/0019 , A61K9/1271 , A61K31/675 , A61K31/704 , A61K31/7068 , A61K45/06 , A61K47/6951 , B82Y5/00 , A61K2300/00
摘要： The present invention is directed generally to formulations of a TLR agonist preferably a TLR8 agonist, and its use in the treatment of various diseases, including combination therapies for treating cancer.
摘要翻译： 本发明一般涉及TLR激动剂优选TLR8激动剂的制剂，以及其在治疗各种疾病中的用途，包括用于治疗癌症的组合疗法。
-
公开(公告)号：US08242106B2
公开(公告)日：2012-08-14
申请号：US12533596
申请日：2009-07-31
IPC分类号： A61K31/55 , C07D223/16
CPC分类号： A61K31/55 , A61K9/0019 , A61K9/08 , A61K9/19 , A61K31/724 , A61K47/40 , A61K47/48969 , A61K47/6951 , B82Y5/00 , C07D223/16 , C08B37/0012 , Y02A50/393
摘要： The present invention is directed generally to stable formulations of a TLR agonist preferably a TLR7 or a TLR8 agonist, for use in the treatment of cancer, preferably solid tumors and lymphomas. Specifically, the present invention is directed to stable formulations of up to 50 mg/ml of a TLR agonist which comprise a cyclodextrin.
摘要翻译： 本发明一般涉及用于治疗癌症，优选实体瘤和淋巴瘤的TLR激动剂优选TLR7或TLR8激动剂的稳定制剂。 具体地，本发明涉及高达50mg / ml的包含环糊精的TLR激动剂的稳定制剂。
-
公开(公告)号：US20110118235A1
公开(公告)日：2011-05-19
申请号：US12859182
申请日：2010-08-18
申请人： James Jeffry Howbert , Gregory Dietsch , Robert Hershberg , Laurence E. Burgess , George A. Doherty , C. Todd Eary , Robert D. Groneberg , Zachary Jones
发明人： James Jeffry Howbert , Gregory Dietsch , Robert Hershberg , Laurence E. Burgess , George A. Doherty , C. Todd Eary , Robert D. Groneberg , Zachary Jones
IPC分类号： A61K31/55 , C07D403/10 , A61P37/02
CPC分类号： C07D223/16 , A61K31/4025 , A61K31/55 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/06 , C07D403/10 , C07D403/14
摘要： Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, infectious disease, inflammatory disorder, graft rejection, and graft-verses-host disease.
摘要翻译： 提供了可用于通过Toll样受体TLR7和/或TLR8调节信号传导的组合物和方法。 组合物和方法可用于治疗或预防疾病，包括癌症，自身免疫性疾病，感染性疾病，炎性疾病，移植物排斥反应和移植物宿主病。
-
公开(公告)号：US08691809B2
公开(公告)日：2014-04-08
申请号：US12859178
申请日：2010-08-18
申请人： James Jeffry Howbert , Gregory Dietsch , Robert Hershberg , Laurence E. Burgess , Joseph P. Lyssikatos , Brad Newhouse , Hong Woon Yang
发明人： James Jeffry Howbert , Gregory Dietsch , Robert Hershberg , Laurence E. Burgess , Joseph P. Lyssikatos , Brad Newhouse , Hong Woon Yang
IPC分类号： A61K31/55 , C07D223/16 , A61P11/06 , A61P37/02 , A61P35/00
CPC分类号： A61K31/55 , C07D223/14 , C07D223/16 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/10 , C07D405/04 , C07D405/10
摘要： Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, infectious disease, inflammatory disorder, graft rejection, and graft-verses-host disease.
摘要翻译： 提供了可用于通过Toll样受体TLR7和/或TLR8调节信号传导的组合物和方法。 组合物和方法可用于治疗或预防疾病，包括癌症，自身免疫性疾病，感染性疾病，炎性疾病，移植物排斥反应和移植物宿主病。
-
公开(公告)号：US20130018042A1
公开(公告)日：2013-01-17
申请号：US13550192
申请日：2012-07-16
CPC分类号： A61K31/55 , A61K9/0019 , A61K9/08 , A61K9/19 , A61K31/724 , A61K47/40 , A61K47/48969 , A61K47/6951 , B82Y5/00 , C07D223/16 , C08B37/0012 , Y02A50/393
摘要： The present invention is directed generally to stable formulations of a TLR agonist preferably a TLR7 or a TLR8 agonist, for use in the treatment of cancer, preferably solid tumors and lymphomas. Specifically, the present invention is directed to stable formulations of up to 50 mg/ml of a TLR agonist which comprise a cyclodextrin.
摘要翻译： 本发明一般涉及用于治疗癌症，优选实体瘤和淋巴瘤的TLR激动剂，优选TLR7或TLR8激动剂的稳定制剂。 具体地，本发明涉及高达50mg / ml的包含环糊精的TLR激动剂的稳定制剂。
-
公开(公告)号：US20110092485A1
公开(公告)日：2011-04-21
申请号：US12859178
申请日：2010-08-18
申请人： James Jeffry Howbert , Gregory Dietsch , Robert Hershberg , Laurence E. Burgess , Joseph P. Lyssikatos , Brad Newhouse , Hong Woon Yang
发明人： James Jeffry Howbert , Gregory Dietsch , Robert Hershberg , Laurence E. Burgess , Joseph P. Lyssikatos , Brad Newhouse , Hong Woon Yang
IPC分类号： A61K31/55 , C07D223/16 , A61P11/06 , A61P37/02 , A61P35/00
CPC分类号： A61K31/55 , C07D223/14 , C07D223/16 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/10 , C07D405/04 , C07D405/10
摘要： Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, infectious disease, inflammatory disorder, graft rejection, and graft-verses-host disease.
-
公开(公告)号：US20100029585A1
公开(公告)日：2010-02-04
申请号：US12533596
申请日：2009-07-31
IPC分类号： A61K31/724 , A61P35/00
CPC分类号： A61K31/55 , A61K9/0019 , A61K9/08 , A61K9/19 , A61K31/724 , A61K47/40 , A61K47/48969 , A61K47/6951 , B82Y5/00 , C07D223/16 , C08B37/0012 , Y02A50/393
摘要： The present invention is directed generally to stable formulations of a TLR agonist preferably a TLR7 or a TLR8 agonist, for use in the treatment of cancer, preferably solid tumors and lymphomas. Specifically, the present invention is directed to stable formulations of up to 50 mg/ml of a TLR agonist which comprise a cyclodextrin.
摘要翻译： 本发明一般涉及用于治疗癌症，优选实体瘤和淋巴瘤的TLR激动剂，优选TLR7或TLR8激动剂的稳定制剂。 具体地，本发明涉及高达50mg / ml的包含环糊精的TLR激动剂的稳定制剂。
-
公开(公告)号：US09216192B2
公开(公告)日：2015-12-22
申请号：US13550192
申请日：2012-07-16
IPC分类号： C07D223/16 , C07D227/10 , A61K31/55 , A61K31/724 , A61K9/00 , A61K9/08 , A61K9/19 , A61K47/48 , B82Y5/00 , C08B37/16
CPC分类号： A61K31/55 , A61K9/0019 , A61K9/08 , A61K9/19 , A61K31/724 , A61K47/40 , A61K47/48969 , A61K47/6951 , B82Y5/00 , C07D223/16 , C08B37/0012 , Y02A50/393
摘要： The present invention is directed generally to stable formulations of a TLR agonist preferably a TLR7 or a TLR8 agonist, for use in the treatment of cancer, preferably solid tumors and lymphomas. Specifically, the present invention is directed to stable formulations of up to 50 mg/ml of a TLR agonist which comprise a cyclodextrin.
摘要翻译： 本发明一般涉及用于治疗癌症，优选实体瘤和淋巴瘤的TLR激动剂，优选TLR7或TLR8激动剂的稳定制剂。 具体地，本发明涉及高达50mg / ml的包含环糊精的TLR激动剂的稳定制剂。
-
公开(公告)号：US08524702B2
公开(公告)日：2013-09-03
申请号：US12859182
申请日：2010-08-18
申请人： James Jeffry Howbert , Gregory Dietsch , Robert Hershberg , Laurence E. Burgess , George A. Doherty , C. Todd Eary , Robert D. Groneberg , Zachary Jones
发明人： James Jeffry Howbert , Gregory Dietsch , Robert Hershberg , Laurence E. Burgess , George A. Doherty , C. Todd Eary , Robert D. Groneberg , Zachary Jones
IPC分类号： A61P35/00 , A61K31/55 , C07D223/16
CPC分类号： C07D223/16 , A61K31/4025 , A61K31/55 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/06 , C07D403/10 , C07D403/14
摘要： Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, infectious disease, inflammatory disorder, graft rejection, and graft-verses-host disease.
-
-
-
-
-
-
-
-
搜索结果
9 条记录 (耗时 0.033 秒)
